FDA Guidance Aims To Cut Down On Incomplete De Novo Submissions

To help make the review process more efficient, the US agency has published a final guidance that goes into effect in early October that lists items sponsors should submit when filing a de novo application. The FDA has created two checklists to make it easy on de novo sponsors to keep track of the documents and format them appropriately for agency review.

Guidance word in red keyboard buttons

More from Regulation

More from Policy & Regulation